Global bladder cancer market was valued at $5,920 million in 2025 and is growing at a CAGR of 6.4% during the forecast period (2026-2035). Active interactions with regulatory agencies and streamlined submission pathways promote the market growth of innovative therapies by enabling quicker market entry. This trend is reflected in ongoing regulatory engagements that focus on optimizing approval processes and facilitating access to advanced treatment options for patients with unmet medical needs. For instance, in January 2026, ImmunityBio is in talks with the FDA about possibly resubmitting its supplemental Biologics License Application (sBLA) for ANKTIVA to treat BCG-unresponsive papillary non-muscle invasive bladder cancer (NMIBC). The FDA requested additional information, which does not require new clinical trials, to aid in their evaluation, with the company set to provide this data within 30 days. Long-term studies have indicated a 96% bladder cancer-specific survival rate and over 80% bladder preservation at three years among 80 patients. ANKTIVA has been launched in the US, along with expanded approvals in the UK and Saudi Arabia, and conditional EU approval. Recent discussions with the FDA highlighted high disease-specific survival rates and a favorable safety profile, addressing current treatment standards and challenges faced by BCG-unresponsive patients.

North America biological data visualization market stood at $281.5 million in 2025 and is expected to expand to $665.6 million by 2035, registering a CAGR of 9.1% over the 2026 to 2035 period. AI-driven analytics and scalable cloud platforms are transforming biological data visualization workflows across North America. Research groups, pharmaceutical and biotech organizations, and academic labs are increasingly adopting tools that embed machine learning and cloud-native capabilities directly into visualization systems. These technologies automate pattern recognition, accelerate interpretation of complex datasets such as single-cell profiles and multiomic outputs, and enable collaboration across distributed teams.

North America cloud database and DBaaS market was valued at $10.3 billion in 2025 and is projected to reach $49.8 billion by 2035, growing at a CAGR of 17.1% during the forecast period (2026–2035). North American enterprises are increasingly adopting multi-model and cloud-native database solutions to meet the demands of modern applications, AI workloads, and real-time analytics. Organizations across BFSI, IT, healthcare, and retail are moving beyond traditional relational databases to integrate document, vector, and key-value databases within cloud and hybrid architectures. This shift allows businesses to handle diverse workloads efficiently, scale rapidly, and ensure compliance while supporting advanced analytics and AI initiatives.

The North America smart transportation market stood at $2.9 billion in 2025 and is expected to expand to $6.5 billion by 2035, registering a CAGR of 8.6% over the 2026 to 2035 period. North America’s smart transportation landscape is being reshaped by public sector investment in intelligent systems that use real-time data and digital tools to manage traffic, reduce congestion, and improve mobility. Federal programs such as the U.S. Department of Transportation’s ITS4US Deployment Program are funding multimodal projects that integrate connected vehicle technology, adaptive signal control, and data platforms to support scalable, connected transit networks. 

Global biosensors market was valued at $34.4 billion in 2025 and is growing at a CAGR of 9.6% during the forecast period (2026-2035). Technological advancements in biosensing increasingly focus on multi-molecule detection platforms, enabling the simultaneous and continuous monitoring of multiple biomarkers in real time. These platforms improve diagnostic depth and support more comprehensive physiological insights compared to single-analyte sensors. Market growth is further driven by sensor miniaturization, which allows minimally invasive or pain-free applications, along with AI-enabled analytics that enhance data interpretation, trend prediction, and clinical relevance. In parallel, smartphone integration has become a critical enabler, improving device accessibility, user engagement, and real-time data transmission within digital health ecosystems.

registering a CAGR of 11.6% over the 2026–2035 period. India’s smart transportation evolution is increasingly shaped by the rapid adoption of digital travel systems and expanding transport networks that address mobility demand across modes. As urban populations grow and travel patterns become more complex, national and city authorities are integrating digital ticketing, real-time information, and automated tolling into core transport infrastructure. These shifts are not only improving passenger convenience and operational efficiency but also enabling interoperable systems that span railways, metros, buses, and highways.

global Nanomedicine market reached a valuation of $265.1 billion in 2025 and is expected to expand to $661.6 billion by 2035, registering a CAGR of 9.7% from 2026 to 2035. The rapid rise in chronic noncommunicable diseases (NCDs) such as cardiovascular disease, cancer, diabetes, and respiratory conditions is a fundamental driver reshaping the global nanomedicine landscape. These conditions are responsible for the majority of premature deaths worldwide and place intensive demands on healthcare systems seeking more effective, targeted treatments. Nanomedicine, with its capacity for precision drug delivery, enhanced bioavailability, and reduced systemic toxicity, directly addresses critical limitations of conventional therapies and is increasingly viewed as essential in managing complex, long-term health conditions.

global Biological data visualization market stood at $720.1 million in 2025 and is expected to grow to $1,639.8 million by 2035, registering a CAGR of 8.7% from 2026 to 2035. The global generation of biological data has reached unprecedented levels, creating a critical need for platforms that help researchers interpret complex datasets efficiently. Public repositories such as EMBL-EBI and sequence archives like NCBI GenBank reflect a massive accumulation of raw biological information that must be accessed, analyzed, and visualized across genomics, imaging, and multi-omics disciplines. The European Molecular Biology Laboratory’s European Bioinformatics Institute (EMBL-EBI), one of the world’s leading sources of public biomolecular data, recorded over 16 petabytes of new data submissions in 2024, bringing total cumulative data to approximately 123 petabytes. 

European smart transportation market stood at $3.1 billion in 2025 and is expected to grow to $6.9 billion by 2035, registering a CAGR of 8.0% from 2026 to 2035. Digital technologies are now central to the transformation of Europe’s transport landscape. The European Union has defined the digitalisation of mobility as a core element of its long?term policy to make transport cleaner, safer, more efficient, and resilient. Key technologies such as artificial intelligence, the Internet of Things, cloud and edge computing, and 5G networks are enabling connected mobility solutions that improve traffic management, multimodal coordination, and real?time service delivery across road, rail, air, and maritime sectors.

European artificial tear market was valued at $1,150.0 million in 2025 and is growing at a CAGR of 4.4% during the forecast period (2026-2035). Recent European Commission approvals for new ophthalmic formulations are expediting market entry and expanding treatment options for patients with moderate to severe dry eye disease (DED). These regulatory developments are strengthening the availability of advanced therapies across Europe and selected MENA regions, thereby supporting overall market growth. For instance, in October 2024, Novaliq and Laboratoires Théa received European Commission approval for ciclosporin 0.1% eye drops solution, branded as Vevizye, for treating dry eye disease (DED). Laboratoires Théa will commercialize the product in Europe and select Middle Eastern and North African countries. Previously approved by the FDA as VEVYE, Vevizye targets moderate to severe DED in adults unresponsive to tear substitutes. Its efficacy was demonstrated in the ESSENCE-1 and ESSENCE-2 clinical trials, focusing on changes in total corneal fluorescein staining (tCFS) scores.